We are international
Donate
• IMF TV TEXT SIZE   



XIIth International Myeloma Workshop, Day 3, February 28, 2009

  • 08:15-10:15 Consensus Panel
  • 10:30-12:30 Transplant
  • 13:30-15:00 Clinical - Phase II/III Studies
  • 13:30-15:00 Clinical Care
  • 13:30-15:00 Clinical - Basic Biology - Research II
  • 15:30-17:30 Future Directions and Strategies in the Evaluation and Treatment of Clonal Plasma Cell Disorders (Sponsored by Celgene)
Complete Program Listing

2009 IMW Saturday Sessions
previous     next      view all

Multiple Myeloma - Transplant
Post Transplant Maintenance
XIIth International Myeloma Workshop in Washington, DC
Thierry Facon, M.D.
Hôpital Claude Huriez
Lille, France

Oral Presentations – Clinical – Phase II/III Studies - II
Note: The video for Dr. Offidani's presentation is incomplete. As soon as a complete copy is located, we will post his talk.
HOVON-50 Final Analysis of Thalidomide Combined with Adriamycine, Dexamethasone and HDM
XIIth International Myeloma Workshop in Washington, DC
Henk Lokhorst, M.D.
University Hospital
Rotterdam, Netherlands

Long-term Follow-up Results of IFM9903 and IFM9904 Rrials: RIC versus ASCT
XIIth International Myeloma Workshop in Washington, DC
Phillipe Moreau, M.D.
Hopital de Nantes
Nantes, France

Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in Myeloma – a Prospective Trial
XIIth International Myeloma Workshop in Washington, DC
Gösta Gahrton, M.D.
Karolinska Institute
Huddinge University Hospital
Stockholm, Sweden

A Phase III Study of MEL200 versus MEL100 in Newly Diagnosed Myeloma Young Patients
XIIth International Myeloma Workshop in Washington, DC
Federica Cavallo, M.D.
Ospedale San Giovanni Battista
Torino, Italy

A Randomized Phase I Study of Melphalan and Bortezomib for Autologous Transplant in Myeloma
XIIth International Myeloma Workshop in Washington, DC
Jonathan Kaufman, M.D.
Winship Cancer Institute
Emory University
Atlanta, Georgia

Future Directions and Strategies in the Evaluation and Treatment of Clonal Plasma Cell Disorders
Monoclonal Gammopathy of Undetermined Significance (MGUS): A Disease in Progression
XIIth International Myeloma Workshop in Washington, DC
Ola Landgren, M.D.
National Cancer Institute
Bethesda, Maryland

Immunophenotyping of Plasma Cell Disorders
XIIth International Myeloma Workshop in Washington, DC
Jesus San Miguel, M.D.
University Hospital
Salamanca, Spain

Can We Treat MGUS and Smouldering Myeloma?
XIIth International Myeloma Workshop in Washington, DC
Jean-Luc Harousseau, M.D.
Hopital Hotel Dieu
Nantes, France

Novel Agents in the Treatment of POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Multiple Myeloma, and Skin Changes)
XIIth International Myeloma Workshop in Washington, DC
Angela Dispenzieri, M.D.
Mayo Clinic
Rochester, Minnesota

previous     next      view all